SG3 Management’s Regenxbio RGNX Stock Holding History

SG3 Management’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-15,000	Closed	-$583K	–	1209
2021 Q2	$583K	Hold	15,000	–	–	0.02%	624
2021 Q1	$512K	Buy	+15,000	New	+$640K	0.01%	769

Other funds holding RGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SG3 Management's RGNX Position: Q2 2021 in Review

SG3 Management sold out of Regenxbio (RGNX) in Q2 2021, closing a stake of 15,000 shares — an estimated $536K sold.

SG3 Management first reported a position in RGNX in Q1 2019 and held it in 2 quarters. The position peaked at $512K in Q1 2021. 172 funds tracked by Wall St. Rank hold RGNX as of Q2 2021.

SG3 Management reported no remaining Regenxbio position as of Q2 2021 after selling out during the quarter.
SG3 Management sold 15,000 Regenxbio shares in Q2 2021, an estimated $536K.
SG3 Management first reported a position in Regenxbio in Q1 2019 and held it in 2 quarters.
SG3 Management's Regenxbio position peaked at $512K in Q1 2021.
172 funds tracked by Wall St. Rank held Regenxbio as of Q2 2021.

Based on SG3 Management's 13F filing for Q2 2021, filed 16 Aug 2021.